Natural killer cells & Cancer

Our lab develops translational means of promoting innate immunity, primarily the one mediated by natural killer (NK) cells, against various cancers such as solid tumors and hematological malignancies. Our approach consists of monoclonal antibodies that inhibit proteolytic cleavage of key extracellular proteins – NK cell activating receptors and ligands. Our antibodies function in a substrate-specific manner. We envision that our antibodies will help reveal new mechanistic insights and enhance treatment for human cancers.